Bristol-Myers Squibb Co vs First Trust Cloud Computing ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while First Trust Cloud Computing ETF trades at $162.57. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while First Trust Cloud Computing ETF pays none, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | SKYY | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $161.09 |
52-Week Low | $42.60 | $104.16 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
SKYY (First Trust Cloud Computing ETF) trades at $162.56, up 1.11% with strong technical momentum as moving averages signal bullish sentiment. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in digital transformation. Recent news highlights institutional interest in cloud computing ETFs as AI adoption accelerates.
The outlook remains positive given cloud migration trends and AI infrastructure investments, though overbought technical indicators suggest potential near-term consolidation. Key risks include regulatory developments in Europe's tech sovereignty initiatives and competitive pressures in the cloud computing sector.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →